OBJECTIVE: To determine the possible role of potassium sensitivity test (PST) in predicting the success of hydrodistention (HD) in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). MATERIAL AND METHODS: Patients who underwent PST before diagnostic cystoscopy and HD were evaluated to collect data regarding the visual analog score (VAS) to assess pain, the voiding diary for frequency of urination/nocturia, mean urine volume per void, interstitial cystitis symptom index, and problem index before HD. Patients were requested to provide the VAS of pain at 1 month and 6 months post-HD. A reduction 2 or more on the VAS of pain was considered as a response adequate to be noted. RESULTS: The median age of the patients was 46 years. The PST was positive for 27 patients (27/39; 69.2%). At 1 month post-HD, out of the 27 patients with positive PST, 23 (85.2%) were found to have been responsive to HD and 4 (14.8%) were non-responsive. Of the 12 (12/39; 30.8%) patients who showed a negative PST, 7 (58.3%) were non-responsive and 5 (41.7%) were responsive to HD. A logistic regression analysis revealed that PST (p=0.009) was the only parameter that was able to predict HD efficacy at 1 month post-HD. CONCLUSION: PST was found to be a predictive factor for the short-term efficacy of HD. BPS/IC patients with positive PST are likely to be more susceptible to the damage of mucosal afferent nerve endings, which results in them benefiting from HD to a greater degree.
OBJECTIVE: To determine the possible role of potassium sensitivity test (PST) in predicting the success of hydrodistention (HD) in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). MATERIAL AND METHODS:Patients who underwent PST before diagnostic cystoscopy and HD were evaluated to collect data regarding the visual analog score (VAS) to assess pain, the voiding diary for frequency of urination/nocturia, mean urine volume per void, interstitial cystitis symptom index, and problem index before HD. Patients were requested to provide the VAS of pain at 1 month and 6 months post-HD. A reduction 2 or more on the VAS of pain was considered as a response adequate to be noted. RESULTS: The median age of the patients was 46 years. The PST was positive for 27 patients (27/39; 69.2%). At 1 month post-HD, out of the 27 patients with positive PST, 23 (85.2%) were found to have been responsive to HD and 4 (14.8%) were non-responsive. Of the 12 (12/39; 30.8%) patients who showed a negative PST, 7 (58.3%) were non-responsive and 5 (41.7%) were responsive to HD. A logistic regression analysis revealed that PST (p=0.009) was the only parameter that was able to predict HD efficacy at 1 month post-HD. CONCLUSION: PST was found to be a predictive factor for the short-term efficacy of HD. BPS/IC patients with positive PST are likely to be more susceptible to the damage of mucosal afferent nerve endings, which results in them benefiting from HD to a greater degree.
Authors: Deborah R Erickson; Allen R Kunselman; Christina M Bentley; Kenneth M Peters; Eric S Rovner; Laurence M Demers; Marcia A Wheeler; Susan K Keay Journal: J Urol Date: 2007-02 Impact factor: 7.450
Authors: Sandra H Berry; Marc N Elliott; Marika Suttorp; Laura M Bogart; Michael A Stoto; Paul Eggers; Leroy Nyberg; J Quentin Clemens Journal: J Urol Date: 2011-06-16 Impact factor: 7.450
Authors: E Rovner; K J Propert; C Brensinger; A J Wein; M Foy; A Kirkemo; J R Landis; J W Kusek; L M Nyberg Journal: Urology Date: 2000-12-20 Impact factor: 2.649
Authors: Nasim Zabihi; Tina Allee; Mary Grey Maher; Arthur Mourtzinos; Shlomo Raz; Christopher K Payne; Larissa V Rodríguez Journal: J Urol Date: 2007-01 Impact factor: 7.450
Authors: John K Triantafillidis; Emmanuel Merikas; Dimitrios Nikolakis; Apostolos E Papalois Journal: World J Gastroenterol Date: 2013-01-28 Impact factor: 5.742
Authors: Daniel S Engeler; Andrew P Baranowski; Paulo Dinis-Oliveira; Suzy Elneil; John Hughes; Embert J Messelink; Arndt van Ophoven; Amanda C Williams Journal: Eur Urol Date: 2013-04-28 Impact factor: 20.096